Unveiling the Anticancer Potential of Curcuma Caesia Roxb. Against Ovarian Cancer: An Indigenous Plant of Assam
DOI:
https://doi.org/10.52783/jns.v14.2605Keywords:
Molecular Docking, 2D interaction, Apoptosis, Cytometry, ZingiberaceaeAbstract
Background: Curcuma caesia Roxb., (Black turmeric), a distinct variety of medicinal herb belonging to Zingiberaceae family is an underexplored plant of Assam, India whose essential oil composition and historic uses set it apart from other members of its family. This study aims to explore the anticancer potential of the phytoconstituents of this herb against ovarian cancer cell line.
Method: In-silico Molecular docking was carried out using PyRx for assessing the effectiveness of active constituents (Isoborneol, Alloaromadendrene, (+)-2-Bornanone, α- Santalol, Ar-tumerone, Megastigma-3,7(E),9-triene, 5,8,11,14,17-Eicosapentaenoic acid methyl ester, Retinal,9-cis, Androstenediol, Camphor, Benzene-1-(1,5-dimethyl-4-hexenyl)-4-methyl, 1,8-Cineole, β-elemene, Bornyl acetate & α-terpineol) against ovarian cancer protein (PDB ID:2NS2) and the potential 2D interaction of the active constituents with binding site of receptor was visualized using Biovia Discovery Studio software. For anticancer study, the rhizomes of Curcuma caesia Roxb., were extracted successively using Soxhlet extraction by hexane, ethyl acetate and methanol extracts respectively and the methanol extract (MECC) containing Androstenediol fraction was assessed for cytotoxicity against PA-1 ovarian cancer cell line by employing the MTT assay.
Result: The outcome of the in-silico analysis demonstrated the highest binding affinity of Androstenediol with a binding score of -7.1 kcal/mol and the 2D interaction revealed that the favorable interacting residues are GLN A:210, ALA A;132, PRO A:135 and VAL A:211 respectively. In cytotoxicity analysis, it was found that there was a dose-dependent reduction in cell viability with an IC50 value of 610 µg/ml. Apoptosis analysis through flow cytometry further revealed that MECC induced significant levels of early apoptosis (23.09%) and late apoptosis (3.50%) with negligible necrosis indicating that the extract primarily triggers programmed cell death.
Conclusion: This study suggests that the presence of bioactive compounds in Curcuma caesia Roxb. holds promising anticancer properties which provides a foundation for the development of novel plant-based anticancer therapies.
Downloads
Metrics
References
Marigoudar JB, Sarkar D, Yuguda YM, Abutayeh RF, Kaur A, Pati A, Mitra D, Ghosh A, Banerjee D, Borah S, Barman K. Role of vitamin D in targeting cancer and cancer stem cell populations and its therapeutic implications. Medical Oncology. 2022 Oct 29;40(1):2.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018 Jan;68(1):7-30.
Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. Journal of ethnopharmacology. 2005 Aug 22;100(1-2):72-9.
Perrone C, Angioli R, Luvero D, Giannini A, Di Donato V, Cuccu I, Muzii L, Raspagliesi F, Bogani G. Targeting BRAF pathway in low-grade serous ovarian cancer. Journal of Gynecologic Oncology. 2024 May 14;35(4):e104.
Karikas GA. Anticancer and chemopreventing natural products: some biochemical and therapeutic aspects. J buon. 2010 Dec;15(4):627-38.
Jiang Y, Lim J, Wu KC, Xu W, Suen JY, Fairlie DP. PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR. British Journal of Pharmacology. 2021 Feb;178(4):913-32.
Kumari A, Shonibare Z, Monavarian M, Arend RC, Lee NY, Inman GJ, Mythreye K. TGFβ signaling networks in ovarian cancer progression and plasticity. Clinical & Experimental Metastasis. 2021 Apr;38:139-61.
Park SA, Kim LK, Park HM, Kim HJ, Heo TH. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer. Oncology Reports. 2022 Mar;47(3):52.
Ji Z, Tian W, Gao W, Zang R, Wang H, Yang G. Cancer-associated fibroblast-derived interleukin-8 promotes ovarian cancer cell stemness and malignancy through the Notch3-mediated signaling. Frontiers in cell and developmental biology. 2021 Jul 1;9:684505.
Rinne N, Christie EL, Ardasheva A, Kwok CH, Demchenko N, Low C, Tralau-Stewart C, Fotopoulou C, Cunnea P. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resistance. 2021;4(3):573.
Meng J, Peng J, Feng J, Maurer J, Li X, Li Y, Yao S, Chu R, Pan X, Li J, Zhang T. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. Journal of Translational Medicine. 2021 Dec;19:1-6.
Chugh NA, Koul A. Altered presence of extra cellular matrix components in murine skin cancer: Modulation by Azadirachta indica leaf extract. Journal of Traditional and Complementary Medicine. 2021 May 1;11(3):197-208.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov;68(6):394-424.
Salehi B, Del Prado-Audelo ML, Cortés H, Leyva-Gómez G, Stojanović-Radić Z, Singh YD, Patra JK, Das G, Martins N, Martorell M, Sharifi-Rad M. Therapeutic applications of curcumin nanomedicine formulations in cardiovascular diseases. Journal of clinical medicine. 2020 Mar 10;9(3):746.
Deshpande AM, Sastry KV, Bhise SB. A contemporary exploration of traditional Indian snake envenomation therapies. Tropical Medicine and Infectious Disease. 2022 Jun 16;7(6):108.
Kuttan R, Bhanumathy P, Nirmala K, George MC. Potential anticancer activity of turmeric (Curcuma longa). Cancer letters. 1985 Nov 1;29(2):197-202.
Simoes e Silva AC, Miranda AS, Rocha NP, Teixeira AL. Neuropsychiatric disorders in chronic kidney disease. Frontiers in pharmacology. 2019 Aug 16;10:932.
Vyas A, Dandawate P, Padhye S, Ahmad A, Sarkar F. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Current pharmaceutical design. 2013 Apr 1;19(11):2047-69.
Akter S, Rahman MA, Hasan MN, Akhter H, Noor P, Islam R, Shin Y, Rahman MH, Gazi MS, Huda MN, Nam NM. Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements. Cells. 2022 Feb 13;11(4):650.
Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. Journal of natural products. 2007 Mar 23;70(3):461-77.
Sharma H, Gupta N, Garg N, Dhankhar S, Chauhan S, Beniwal S, Saini D. Herbal Medicinal Nanoformulations for Psoriasis Treatment: Current State of Knowledge and Future Directions. The Natural Products Journal. 2024 Oct 1;14(7):61-79.
Caunii A, Pribac G, Grozea I, Gaitin D, Samfira I. Design of optimal solvent for extraction of bio–active ingredients from six varieties of Medicago sativa. Chemistry Central Journal. 2012 Dec;6:1-8.
Aratanechemuge Y, Komiya T, Moteki H, Katsuzaki H, Imai K, Hibasami H. Selective induction of apoptosis by ar-turmerone isolated from turmeric (Curcuma longa L) in two human leukemia cell lines, but not in human stomach cancer cell line. International journal of molecular medicine. 2002 May 1;9(5):481-4.
Romijn JC, Verkoelen CF, Schroeder FH. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone‐stimulated growth and drug‐induced cytostatic and cytotoxic effects. The prostate. 1988; 12(1):99-110.
Richardson DL, Eskander RN, O’Malley DM. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA oncology. 2023 Jun 1.
Lv ZD, Liu XP, Zhao WJ, Dong Q, Li FN, Wang HB, Kong B. Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. International journal of clinical and experimental pathology. 2014;7(6):2818.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
